ahlam1399
09-02-2015, 01:41 AM
UPDATE 1-Alexion gets EU approval for drug acquired in Synageva deal
NEW YORK, Sept 1 (Reuters) - Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday an**unced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/497c64bd/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=WN0BMgACwXY:vp-msM81f8A:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=WN0BMgACwXY:vp-msM81f8A:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=WN0BMgACwXY:vp-msM81f8A:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=WN0BMgACwXY:vp-msM81f8A:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=WN0BMgACwXY:vp-msM81f8A:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/WN0BMgACwXY
NEW YORK, Sept 1 (Reuters) - Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday an**unced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/497c64bd/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=WN0BMgACwXY:vp-msM81f8A:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=WN0BMgACwXY:vp-msM81f8A:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=WN0BMgACwXY:vp-msM81f8A:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=WN0BMgACwXY:vp-msM81f8A:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=WN0BMgACwXY:vp-msM81f8A:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/WN0BMgACwXY